Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells

Molecular Carcinogenesis

Volumn 41, Issue 2, 2004, Pages 98-107

  Miyagi, Eri ^a   Braga Basaria, Milena ^a   Hardy, Elena ^a   Vasko, Vasily ^a,b   Burman, Kenneth D ^a   Jhiang, Sissy ^b   Saji, Motoyasu ^a,b   Ringel, Matthew D ^a,b,c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Divisions of Endocrinol and Oncol   (United States)

Author keywords

Cell signaling; Phosphatidylinositol (OH) 3 kinase; Protein kinase B; Thyroid cancer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; DNA; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P85; RAPAMYCIN; THYMIDINE; THYROTROPIN;

CELL CULTURE; CELL LEVEL; CONFERENCE PAPER; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; NONHUMAN; ONCOGENE; ONCOGENE PTC3; ONCOGENE RET; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; SENSITIZATION; SERUM; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA; INSULIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION; THYMIDINE; THYROID GLAND; THYROID NEOPLASMS; TRANSFECTION;

EID: 5044234080     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20042     Document Type: Conference Paper

References (71)

1. Fagin JA. Minireview: Branded from the Start-Distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 2002;16:903-911.
2. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-563.
3. Santoro M, Carlomagno F, Hay ID, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992;89:1517-1522.
4. Lanzi C, Borrello MG, Bongarzone I, et al. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. Oncogene 1992;7:2189-2194.
5. Bounacer A, Wicker R, Caillou B, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997;15:1263-1273.
6. Kitamura Y, Minobe K, Nakata T, et al. Ret/PTC3 is the most frequent form of gene rearrangement in papillary thyroid carcinomas in Japan. J Hum Genet 1999;44:96-102.
7. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 2000;85:1170-1175.
8. Jhiang SM. The RET proto-oncogene in human cancers. Oncogene 2000;19:5590-5597.
9. Klugbauer S, Pfeiffer P, Gassenhuber H, Beimfohr C, Rabes HM. RET rearrangements in radiation-induced papillary thyroid carcinomas: High prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes. Genomics 2001;73:149-160.
10. Smanik PA, Furminger TL, Mazzaferri EL, Jhiang SM. Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma. Hum Mol Genet 1995;4:2313-2318.
11. Nikiforov YE, Koshoffer A, Nikiforova M, Stringer J, Fagin JA. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene 1999;18:6330-6334.
12. Santoro M, Dathan NA, Berlingieri MT, et al. Molecular characterization of RET/PTC3: A novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994;9:509-516.
13. Jhiang SM, Sagartz JE, Tong Q, et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996;137:375-378.
14. Portella G, Salvatore D, Botti G, et al. Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene. Oncogene 1996;13:2021-2026.
15. Sagartz JE, Jhiang SM, Tong Q, Capen CC. Thyroid-stimulating hormone promotes growth of thyroid carcinomas in transgenic mice with targeted expression of the ret/ PTC1 oncogene. Lab Invest 1997;76:307-318.
16. Powell DJ, Russell J, Nibu K, et al. The RET/PTC3 oncogene: Metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 1998;58:5523-5528.
17. Ishizaka Y, Kobayashi S, Ushijima T, Hirohashi S, Sugimura T, Nagao M. Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 1991;6:1667-1672.
18. Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T. Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 1994;172:255-260.
19. Cinti R, Yin L, Ilc K, et al. RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenet Cell Genet 2000;88:56-61.
20. Sheils OM, O'Eary JJ, Uhlmann V, Lattich K, Sweeney EC. ret/PTC-1 activation in Hashimoto Thyroiditis. Int J Surg Pathol 2000;8:185-189.
21. Nikiforova MN, Caudill CM, Biddinger P, Nikiforov YE. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol 2002;10:15-22.
22. Minoletti F, Butti MG, Coronelli S, et al. The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2. Genes Chromosomes Cancer 1994;11:51-57.
23. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 1995;11:2459-2467.
24. Cetta F, Gori M, Montalto G, Zuckermann M, Toti P. Different significance of ret/PTC(1) and ret/PTC(3) rearrangements in thyroid carcinogenesis: Lesson from two subgroups of patients with papillary thyroid carcinomas showing the highest incidence of ret/PTC activation. J Clin Endocrinol Metab 2001;86:1429.
25. Kjellman P, Learoyd DL, Messina M, et al. Expression of the RET proto-oncogene in papillary thyroid carcinoma and its correlation with clinical outcome. Br J Surg 2001;88:557-563.
26. Basolo F, Giannini R, Monaco C, et al. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol 2002;160:247-254.
27. Monaco C, Visconti R, Barone MV, et al. The RFG oligomerization domain mediates kinase activation and relocalization of the RET/PTC3 oncoprotein to the plasma membrane. Oncogene 2001;20:599-608.
28. Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res 1995;55:5617-5620.
29. Chiariello M, Visconti R, Carlomagno F, et al. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): Evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene 1998;16:2435-2445.
30. De Vita G, Melillo RM, Carlomagno F, et al. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res 2000;60:3727-3731.
31. Hennige AM, Lammers R, Arlt D, et al. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: Possible implication for transforming activity in NIH3T3 cells. Mol Cell Endocrinol 2000;167:69-76.
32. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000;275:3568-3576.
33. Califano D, Rizzo C, D'Alessio A, et al. Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells. J Biol Chem 2000;275:19297-19305.
34. Hennige AM, Lammers R, Hoppner W, et al. Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology 2001;142:4441-4447.
35. Carlomagno F, Vitagliano D, Guida T, et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002;62:1077-1082.
36. Durick K, Wu RY, Gill GN, Taylor SS. Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain. J Biol Chem 1996;271:12691-12694.
37. Durick K, Gill GN, Taylor SS. She and enigma are both required for mitogenic signaling by Ret/ptc2. Mol Cell Biol 1998;18:2298-2308.
38. Xing S, Furminger TL, Tong Q, Jhiang SM. Signal transduction pathways activated by RET oncoproteins in PC 12 pheochromocytoma cells. J Biol Chem 1998;273:4909-4914.
39. Cho JY, Sagartz JE, Capen CC, Mazzaferri EL, Jhiang SM. Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice. Oncogene 1999;18:3659-3665.
40. Barone MV, Sepe L, Melillo RM, et al. RET/PTC1 oncogene signaling in PC CI 3 thyroid cells requires the small GTP-binding protein Rho. Oncogene 2001;20:6973-6982.
41. Ringel MD, Hayre N, Saito J, et al. Overexpression and over-activation of Akt in thyroid carcinoma. Cancer Res 2001;61:6105-6111.
42. Specht MC, Barden CB, Fahey TJ III. p44/p42-MAP kinase expression in papillary thyroid carcinomas. Surgery 2001;130:936-940.
43. Miyakawa M, Tsushima T, Murakami H, Wakai K, Isozaki O, Takano K. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J 2003;50:77-83.
44. Coulonval K, Vandeput F, Stein RC, Kozma SC, Lamy F, Dumont JE. Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochem J 2000;348:351-358.
45. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: A critical evaluation of in vitro models. Endocr Rev 2001;22:631-656.
46. Saito J, Kohn AD, Roth RA, et al. Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid 2001;11:339-351.
47. De Vita G, Berlingieri MT, Visconti R, et al. Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. Cancer Res 2000;60:3916-3920.
48. Vasko V, Saji M, Hardy E, et al. Aktactivation and localization correlate with tumor invasion and oncogene expression in thyroid cancer. J Mol Genet 2004;41:161-170.
49. Ambesi-Impiombato FS, Villone G. The FRTL-5 thyroid cell strain as a model for studies on thyroid cell growth. Acta Endocrinol Suppl (Copenh) 1987;281:242-245.
50. Valente WA, Vitti P, Kohn LD, et al. The relationship of growth and adenylate cyclase activity in cultured thyroid cells: Separate bioeffects of thyrotropin. Endocrinology 1983;112:71-79.
51. Saji M, Isozaki O, Tsushima T, et al. The inhibitory effect of iodide on growth of rat thyroid (FRTL-5) cells. Acta Endocrinol (Copenh) 1988;119:145-151.
52. Jin S, Hornicek FJ, Neylan D, Zakarija M, McKenzie JM. Evidence that adenosine 3′,5′-monophosphate mediates stimulation of thyroid growth in FRTL5 cells. Endocrinology 1986;119:802-810.
53. Takano A, Usui I, Haruta T, et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 2001;21:5050-5062.
54. Viglietto G, Chiappetta G, Martinez-Tello FJ, et al. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995;11:1207-1210.
55. Sugg SL, Zheng L, Rosen IB, Freeman JL, Ezzat S, Asa SL. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: Implications for metastatic potential? J Clin Endocrinol Metab 1996;81:3360-3365.
56. Pacini F, Elisei R, Romei C, Pinchera A. RET proto-oncogene mutations in thyroid carcinomas: Clinical relevance. J Endocrinol Invest 2000;23:328-338.
57. Cantley LC. The phosphoinositide3-kinase pathway. Science 2002;296:1655-1657.
58. Kimura T, Dumont JE, Fusco A, Golstein J. Insulin and TSH promote growth in size of PC CI3 rat thyroid cells, possibly via a pathway different from DNA synthesis: Comparison with FRTL-5 cells. Eur J Endocrinol 1999;140:94-103.
59. Cass LA, Meinkoth JL. Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation. Oncogene 2000;19:924-932.
60. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome: Two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7:507-515.
61. Tramontano D, Gushing GW, Moses AC, Ingbar SH. Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG. Endocrinology 1986;119:940-942.
62. Saji M, Tsushima T, Isozaki O, et al. Interaction of insulin-like growth factor I with porcine thyroid cells cultured in monolayer. Endocrinology 1987;121:749-756.
63. Williams DW, Wynford-Thomas D, Williams ED. Control of human thyroid follicular cell proliferation in suspension and monolayer culture. Mol Cell Endocrinol 1987;51:33-40.
64. Condorelli G, Formisano P, Miele C, Beguinot F. Thyrotropin regulates autophosphorylation and kinase activity in both the insulin and the insulin-like growth factor-I receptors in FRTL5 cells. Endocrinology 1992;130:1615-1625.
65. Koide T, Ono Y, Ito Y, et al. Insulin-like growth factor-I potentiates protein synthesis induced by thyrotropin in FRTL-5 cells: Comparison of induction of protein synthesis and DNA synthesis. Endocr J 1998;45:151-163.
66. Medina DL, Velasco JA, Santisteban P. Somatostatin is expressed in FRTL-5 thyroid cells and prevents thyrotropin-mediated down-regulation of the cyclin-dependent kinase inhibitor p27kip1. Endocrinology 1999;140:87-95.
67. Van Keymeulen A, Dumont JE, Roger PP. TSH induces insulin receptors that mediate insulin costimulation of growth in normal human thyroid cells. Biochem Biophys Res Commun 2000;279:202-207.
68. Clément S, Refetoff S, Robaye B, Dumont JE, Schurmans S. Low TSH requirement and goiter in transgenic mice overexpressing IGF-I and IGF-I receptor in the thyroid gland. Endocrinology 2001;142:5131-5266.
69. Frittitta L, Sciacca L, Catalfamo R, et al. Functional insulin receptors are overexpressed in thyroid tumors: Is this an early event in thyroid tumorigenesis? Cancer 1999;85:492-498.
70. Wang J, Knauf JA, Basu S, et al. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol Endocrinol 2003;17:1425-1436.
71. Braga-Basaria M, Hardy Allrbitton E, Gottfried R, Burman KD, Saji M, Ringel MD. 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) activity against thyroid cancer cell lines correlates with Hsp90 levels. J Clin Endocrinol Metab 2004;84:2982-2988.